Capital at risk. Past performance is not a reliable indicator of current or future results and should not be the sole factor of consideration when selecting a product or strategy.
The listed funds are not an exhaustive list of funds available. Visit www.funds.troweprice.com to see the full range of funds offered by T. Rowe Price, including those that consider environmental and social characteristics as part of their investment process. For up to date information regarding any T. Rowe Price fund's investment strategy, please see the relevant fund KID and prospectus.
SICAV III
T. Rowe Price Health Sciences Equity Fund
An actively managed, diversified all-cap portfolio of typically 220-250 companies that are involved in the research, development, production, or distribution of products or services related to health sciences. The fund is categorised as Article 8 under Sustainable Finance Disclosure Regulation (SFDR).
ISIN LU2488120796
Overview
Strategy
Fund Summary
We seek to invest in a portfolio of companies which we believe have the greatest ability to bring new products and technologies to the health care marketplace that will improve the practice of medicine and satisfy unmet clinical needs. Our process emphasises fundamental, bottom-up analysis with deep industry expertise and reach across the health care sector. The promotion of environmental and/or social characteristics is achieved through the fund's commitment to maintain at least 10% of the value of its portfolio invested in Sustainable Investments, as defined by the SFDR. Additionally, we apply a proprietary responsible screen (exclusion list). The manager is not constrained by the fund’s benchmark, which is used for performance comparison purposes only.
Team

Ziad Bakri,
Portfolio Manager
Portfolio Manager
Ziad Bakri is a portfolio manager in the U.S. Equity Division of T. Rowe Price.
Portfolio Manager
since
2011
Years at T. Rowe Price
9
Years investment experience
15